1 Top Dividend King to Buy for The Long Haul

NYSE: MO | Altria Group, Inc. News, Ratings, and Charts

MO – With the Fed’s intention to continue hiking interest rates threatening to keep the underperforming stock market in perpetual turmoil, dividend Altria Group, Inc (MO) could help investors secure a steady income stream. Read on….

Although the Chinese economy reopened sooner than expected, and Europe registered an uptick in industrial activity due to a warmer-than-expected winter, analysts expect the global economy to witness a slowdown this year.

Moreover, with the Fed determined to keep raising rates in the foreseeable future and other headwinds acting to catalyze an economic slowdown, this decoupling between European and American markets is expected to continue in 2023.

Barclays strategists summed up the market scenario stateside by commenting, “The rally is losing steam in equities, while it is gathering pace in bonds. This is starting to resemble a classic recession playbook, with investors selling equities to buy bonds.”

In such a scenario, estimates of investment returns based on capital appreciation have temporarily gone out of the window. Hence, investing in dividend-paying stocks could ensure consistent income generation to endure a topsy-turvy market in the foreseeable future.

Altria Group, Inc. (MO) operates as a manufacturer and seller of smokable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands. In addition, it also sells oral nicotine pouches under on! brand.

MO’s excellent business performance has enabled it to achieve an impressive track record of returning capital to its shareholders. Over the past three years, MO’s revenue has grown at a 1.5% CAGR. During the same period, the company also registered EBITDA and net income growth of 1.1% and 38.6%, respectively.

The stock has gained 2.2% over the past six months to close the last trading session at $44.81.

Let’s closely examine the factors that make it worthy of investment.

Solid Financials

For the fiscal 2022 third quarter ended September 30, MO’s operating income increased 5.5% year-over-year to $3.11 billion. During the same period, the net earnings attributable to MO came in at $224 million, compared to a loss of $2.72 billion during the previous-year quarter.

As a result, the company adjusted quarterly EPS increased by 4.9% year-over-year to $1.28.

Consistent Dividend Payouts

On January 10, MO paid its regular quarterly dividend of $0.94 per share. The company pays $3.76 annually as dividends, translating to a forward yield of 8.39% at the current price, better than the four-year average dividend yield of 7.43%. It currently pays a substantial 76.63% of its earnings as dividends.

MO has increased its dividends for 53 consecutive years. The company’s dividend payouts have grown at a 7.7% CAGR over the past five years.

Excellent Capital Allocation by Management

MO’s trailing 12-month gross profit margin of 67.66% is higher than the industry average of 31.37%. Also, the company’s trailing-12-month EBITDA margin and net income margin of 60.06% and 22.71% comfortably exceed the industry averages of 11.14% and 4.12%, respectively.

Additionally, MO’s trailing-12-month ROTC and ROTA of 31.17% and 13.84% are significantly higher than the respective industry averages of 6.17% and 3.62%.

Optimistic Analyst Estimates

MO’s revenue and EPS for the current fiscal ending December 31, 2023, are expected to increase 1.5% and 3.9% year-over-year to $21.09 billion and $5.00, respectively. Revenue and EPS are expected to increase by 0.7% and 4.7% in the next fiscal year to come in at $21.24 and $5.24, respectively.

POWR Ratings Reflect Promising Prospects

MO’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. MO has an A grade for Quality, consistent with its impressive profitability.

MO is ranked #3 of 9 stocks in the A-rated Tobacco industry.

Click here to see the additional POWR Ratings for MO’s Growth, Sentiment, Momentum, Value, and Stability.

Bottom Line

To reinvent itself with changing times, MO has been explicit about its goal of Moving Beyond Smoking.

In pursuit of this goal, the company announced a strategic alliance with JT Group to pursue a global smoke-free partnership. The companies announced a joint venture for the marketing and commercialization of heated tobacco sticks in the United States. This would help MO tap a broader market segment that prefers smoke-free tobacco products to smokable ones.

Given MO’s solid fundamentals and future readiness, which support the company’s income generation track record and potential, it is expected to be a source of predictable and sustained returns in an unpredictable market, mirroring an uncertain macroeconomic climate.

How Does Altria Group, Inc. (MO) Stack up Against Its Peers?

While MO ranks third in its industry group and has an overall POWR Rating of B, which equates to a Buy, investors could also consider looking at its A-rated and B-rated industry peers: Japan Tobacco Inc. (JAPAY), Imperial Brands PLC (IMBBY), and Vector Group Ltd. (VGR).


MO shares were trading at $44.89 per share on Tuesday afternoon, up $0.08 (+0.18%). Year-to-date, MO has declined -1.79%, versus a 4.75% rise in the benchmark S&P 500 index during the same period.


About the Author: Santanu Roy


Having been fascinated by the traditional and evolving factors that affect investment decisions, Santanu decided to pursue a career as an investment analyst. Prior to his switch to investment research, he was a process associate at Cognizant. With a master's degree in business administration and a fundamental approach to analyzing businesses, he aims to help retail investors identify the best long-term investment opportunities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MOGet RatingGet RatingGet Rating
JAPAYGet RatingGet RatingGet Rating
IMBBYGet RatingGet RatingGet Rating
VGRGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Should Investors BEWARE this Market?

The S&P 500 (SPY) has been on a tear since November 1st when the Fed started to make their dovish tilt opening the door to future rate cuts. Unfortunately they keep not happening and start date keeps getting pushed further and further out. That has many wondering if stocks are getting ahead of themselves setting things up for a fall. Thus a good time to tune into what investment veteran Steve Reitmeister has to say about the market outlook along with his trading plan and top picks to stay ahead of the pack. Read on below for more...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Is the Bull Market Growing Tired?

On the one hand it is fun to celebrate the new highs for the S&P 500 (SPY) that came in this Tuesday. On the other hand...it doesn’t make a lot of sense calling into question the next moves for the stock market. Read on below to appreciate investment veteran, Steve Reitmeister’s, market outlook and top picks to outperform.

Read More Stories

More Altria Group, Inc. (MO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MO News